KPP Advisory Services LLC Lowers Stake in Eli Lilly and Company (NYSE:LLY)

KPP Advisory Services LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 2,862 shares of the company’s stock after selling 157 shares during the period. KPP Advisory Services LLC’s holdings in Eli Lilly and Company were worth $2,591,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. New Century Financial Group LLC grew its position in Eli Lilly and Company by 10.0% in the 2nd quarter. New Century Financial Group LLC now owns 2,185 shares of the company’s stock valued at $1,978,000 after acquiring an additional 199 shares in the last quarter. Aldebaran Financial Inc. boosted its stake in shares of Eli Lilly and Company by 17.9% in the second quarter. Aldebaran Financial Inc. now owns 723 shares of the company’s stock valued at $655,000 after purchasing an additional 110 shares during the period. Cetera Investment Advisers grew its holdings in shares of Eli Lilly and Company by 0.3% in the second quarter. Cetera Investment Advisers now owns 224,922 shares of the company’s stock valued at $203,641,000 after purchasing an additional 603 shares in the last quarter. 3Chopt Investment Partners LLC increased its stake in Eli Lilly and Company by 14.8% during the 2nd quarter. 3Chopt Investment Partners LLC now owns 3,746 shares of the company’s stock worth $3,392,000 after buying an additional 483 shares during the period. Finally, Granite Bay Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $323,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 364,810 shares of company stock valued at $339,366,198 over the last quarter. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Berenberg Bank boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Citigroup assumed coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective on the stock. Finally, Bank of America boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $885.56 on Tuesday. The stock has a market cap of $841.64 billion, a P/E ratio of 130.42, a P/E/G ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The stock has a 50 day moving average of $896.50 and a two-hundred day moving average of $844.99. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.